Indication

Refractory Rare Malignant Solid Neoplasm

1 clinical trial

2 drugs

Clinical trial

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab

Status: Recruiting, Estimated PCD: 2026-10-15

Drug

Drug